In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Heinz Drexel
Heinz Drexel Heinz Drexel

Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Feldkirch (Austria)

Specialities : Risk Factors and Prevention , Pharmacology and Pharmacotherapy, Risk Factors and Prevention

20 presentations from this speaker

Management of the heart failure patient with diabetes.

Event : Webinar 2019

  • Session : HFA Webinars 2019
  • Speaker : J Celutkiene (Vilnius,LT), H Drexel (Feldkirch,AT), P Jhund (Glasgow,GB)

Session close

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : H Drexel (Feldkirch,AT)
  • Sponsored by MSD

Welcome and opening remarks

Event : ESC Congress 2019

  • Session : Latest insights into cholesterol management for the post-myocardial infarction patient
  • Speaker : H Drexel (Feldkirch,AT)
  • Sponsored by MSD

Complex cases in atherosclerosis: what to do post-MI?

Event : ESC Congress 2018

  • Session : Assessing atherosclerosis: risks, goals and strategies to minimize cardiovascular risk post-myocardial infarction
  • Speaker : H Drexel (Feldkirch,AT)
  • Sponsored by MSD

Panel discussion and Q&A.

Event : ESC Congress 2018

  • Session : Assessing atherosclerosis: risks, goals and strategies to minimize cardiovascular risk post-myocardial infarction
  • Speaker : E Bohula (Boston,US), S Tokgozoglu (Ankara,TR), AK Gitt (Ludwigshafen,DE), H Drexel (Feldkirch,AT)
  • Sponsored by MSD

Serum uromodulin predicts mortality independently from the presence of type 2 diabetes

Event : Frontiers in CardioVascular Biology 2018

  • Session : Basic Science - Vascular Diseases
  • Speaker : H Drexel (Feldkirch,AT)

The creatinine to uromodulin ratio in serum predicts major cardiovascular events independently from the presence of type 2 diabetes

Event : Frontiers in CardioVascular Biology 2018

  • Session : Basic Science - Cardiac Diseases
  • Speaker : H Drexel (Feldkirch,AT)

Do we need PCSK9 inhibitors in post-MI patients? CON

Event : ESC Congress 2017

  • Session : Do we need PCSK9 inhibitors in post-MI patients?
  • Speaker : H Drexel (Feldkirch,AT)

Do we need PCSK9 inhibitors in post-MI patients? Rebuttal CON

Event : ESC Congress 2017

  • Session : Do we need PCSK9 inhibitors in post-MI patients?
  • Speaker : H Drexel (Feldkirch,AT)

Recent results in clinical trials of blood cholesterol lowering.

Event : ESC Congress 2017

  • Session : Recent results in clinical trials of blood cholesterol lowering
  • Speaker : H Drexel (Feldkirch,AT), E Braunwald (Boston,US), R Collins (Oxford,GB)
  • Sponsored by MSD

Towards a broader understanding of statins

Event : ESC Congress 2017

  • Session : New insights in statin therapy
  • Speaker : H Drexel (Feldkirch,AT)

Evaluation of the creatinine uromodulin ratio as new serum marker for cardiovascular events

Event : ESC Congress 2016

  • Session : Biomarkers in CVD
  • Speaker : H Drexel (Feldkirch,AT)

Non-alcoholic fatty liver disease strongly predicts incident diabetes in patients with coronary artery disease

Event : ESC Congress 2016

  • Session : Dealing with metabolic disorders
  • Speaker : H Drexel (Feldkirch,AT)

PCSK9 inhibitors: ready to embrace? Conclusion.

Event : ESC Congress 2016

  • Session : PCSK9 inhibitors: ready to embrace?
  • Speaker : H Drexel (Feldkirch,AT)

Q&A and panel discussion - Cholesteryl ester transfer protein (CETP) inhibition: emerging science in LDL lowering.

Event : ESC Congress 2016

  • Session : Cholesteryl ester transfer protein (CETP) inhibition: emerging science in LDL lowering
  • Speaker : H Drexel (Feldkirch,AT), U Landmesser (Berlin,DE)
  • Sponsored by MSD

Welcome and introduction - Cholesteryl ester transfer protein (CETP) inhibition: emerging science in LDL lowering.

Event : ESC Congress 2016

  • Session : Cholesteryl ester transfer protein (CETP) inhibition: emerging science in LDL lowering
  • Speaker : H Drexel (Feldkirch,AT), U Landmesser (Berlin,DE)
  • Sponsored by MSD

Statins.

Event : ESC Congress 2015

  • Session : Important drug interactions: what the cardiologist should know
  • Speaker : H Drexel (Feldkirch,AT)

Statins.

Event : ESC Congress 2014

  • Session : Important drug interactions - what you should know!
  • Speaker : H Drexel (Feldkirch,AT)

Lipid lowering agents.

Event : ESC Congress 2013

  • Session : Drug interactions: what the cardiologist should know
  • Speaker : H Drexel (Feldkirch,AT)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are